Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879260 | 0.89 | CDK4 (0.71) | KDRCDK4CCND1PDE4BALDH1A1 | |
| SCHEMBL7816070 | 0.83 | CDK4 (0.78) | KDRCDK4CCND1PDE4BALDH1A1 | |
| SCHEMBL5879259 | 0.82 | KDM4E (0.44) | CDK4CCND1PRKD3ABL1PDGFRB | |
| SCHEMBL5879251 | 0.81 | CDK4 (0.45) | KDRCDK4CCND1ALDH1A1ABL1 | |
| SCHEMBL5879305 | 0.79 | TRPM8 (0.52) | ALDH1A1CYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5879170 | 0.79 | F7 (0.45) | CDK4CCND1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5879151 | 0.79 | BRAF (0.44) | KDRCDK4CCND1ALDH1A1CYP1A2 | |
| SCHEMBL5879171 | 0.79 | CLK1 (0.45) | KDRCDK4CCND1CYP2C19PRKD3 | |
| SCHEMBL5879255 | 0.79 | IGF1R (0.50) | KDRCDK4CCND1CYP2C19GPR84 | |
| SCHEMBL5879252 | 0.79 | PDGFRB (0.50) | KDRCDK4CCND1CYP1A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | KDR 1773/4885CDK4 47/4885CCND1 106/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | KDR 2824/4885CDK4 1989/4885CCND1 405/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | KDR 1667/4885CDK4 50/4885CCND1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.